Neurothera Labs

Phase IIa of SCI-110 in Alzheimerâ€s-related agitation met its primary and secondary endpoints and was safe at all tested doses.

Randomized, double-blind, placebo-controlled crossover study of SCI-210 in children with autism spectrum disorder at Soroka University Medical Center.

Neurothera holds about 54% of CliniQuantum Ltd., an Israeli company applying quantum simulation to make clinical trial analysis more precise.

SCI-110 (THC + CannAmideâ„¢) and SCI-210 (CBD + CannAmideâ„¢) programs for Tourette syndrome, Alzheimerâ€s agitation, autism and status epilepticus.

Neurothera Labs is a clinical-stage pharmaceutical company developing novel cannabinoid-based treatments for central nervous system disorders.

Neurothera Labs invites discussions on partnerships, clinical programs, and investor inquiries.

Neurothera Labs (TSXV: NTLX) develops proprietary cannabinoid-based pharmaceuticals for CNS disorders, with three programs in advanced clinical stages.

NeuroThera Labs reports positive progress in its FDA-approved Phase IIb clinical trial for Tourette syndrome. The trial, conducted across three sites—Yale Child Study Center, Hannover Medical School, and Tel Aviv Sourasky Medical Center—evaluates a potential treatment. Early results suggest the intervention may demonstrate efficacy in managing symptoms.

Oct 2026NewMediaWireNews article

NeuroThera Labs, a subsidiary of SciSparc, pursues FDA orphan drug designation for an adult Tourette syndrome treatment. The company engages RK Strategies, a healthcare-focused government and public affairs firm, to support regulatory efforts.

Sep 2026NasdaqNews article

NeuroThera Labs begins a Phase IIb clinical trial at Hannover Medical School to test **SCI-110**, an oral treatment for Tourette syndrome. The randomized, double-blind study evaluates efficacy, safety, and tolerability against a placebo. The trial follows a cross-over design to assess long-term effects.

Jul 2026GlobeNewswireNews article

NeuroThera acquires a 54% ownership stake in CliniQuantum. The transaction expands NeuroThera’s presence in quantum health diagnostics. CliniQuantum specializes in quantum-based medical imaging solutions.

Jun 2026Investing.comNews article